Serina Therapeutics Q2 net loss $6.4M; cash runway into Q4 2025; SER-252 on track for clinic this year

Serina Therapeutics, Inc.

2025-Q2 EPS reported -$1.15 revenue$130,000

Net loss $6.4M ($0.66/share) vs prior-year net income $5.2M ($0.61/share).
Revenue $130k (NIH grants) vs $51k YoY; R&D spend up 100% to $3.2M.
Cash $6.0M; projects funding into Q4 2025; raised $1.2M net via ATM at avg $5.95.
Lead candidate SER-252 (POZ-apomorphine) on track for Phase 1 in Q4 2025.
Advanced SER-270 (once-weekly injectable) for tardive dyskinesia; appointed Dr. Brannan to board.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.